Innovative, high-quality medical education for clinicians in cardiology and other specialties.
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, PhD, FRCP
Claudia Seikrit, MD
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
James Burton, DM, FRCP
Javed Butler, MD
Ellie Kelepouris, MD, FACP, FAHA
Patrick Rossignol, MD, PhD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
Leonie Kraft, MD
Lucio Manenti, MD, PhD
Emilio Sanchez, MD, PhD
Leadoff Hitter – Spotting High-Risk Players
J.A. Randy Englert, MD, FACC
Extra Innings – Sustaining Victory Beyond the First Game
Matthew Malachowski, Pharm. D., MHA
Turning the Double Play – Comprehensive Secondary Prevention
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Joseph Rossano, MD